

Sonnenschein
SONNENSCHN NATH & ROSENTHAL

RECEIVED
CENTRAL FAX CENTER

MAR 08 2006

One Metropolitan Square
Suite 3000
St. Louis, MO 63102
314.241.1800
314.259.5959 fax
www.sonnenschein.com

Chicago
Kansas City
Los Angeles
New York
San Francisco
St. Louis
Washington, D.C.
West Palm Beach

Facsimile Transmittal Sheet

DATE March 8, 2006


PLEASE DELIVER THE FOLLOWING PAGES TO:

NAME Office of Initial Patent Examination
FAX 571-273-8300
CLIENT/MATTER 60019190-1038

FROM Tara A. Nealey, Ph.D.

TOTAL NUMBER OF PAGES TRANSMITTED, INCLUDING THIS SHEET: 5

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.


Laura L. Albes

March 8, 2006
Date

Type of Paper transmitted: Request for Corrected Filing Receipt

Applicant's Name: David W. Moskowitz

Serial No. (Control No.): 10/820,479 Examiner:

Filing Date March 31, 2004 Art Unit: 1614

Application Title: Use of Angiotensin Receptor Blockers (ARBS) To Treat Diseases Associated With Excess Ace

Original will NOT be mailed

CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission and the Facsimile Transmission Sheet contain information from the law firm of Sonnenschein Nath & Rosenthal which is confidential or privileged. The information is intended to be for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this facsimile information is prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the retrieval of the original documents at no cost to you.

IF YOU DO NOT RECEIVE ALL OF THE PAGES ABOVE, PLEASE CALL 314.241.1800 AS SOON AS POSSIBLE.

SN&R FACSIMILE DEPARTMENT USE ONLY:

TRANSMISSION COMPLETED AT:

DOCUMENT TRANSMITTED BY:

Attorney Docket No. 60019190-1038

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:) Group Art Unit 1614
David W. Moskowitz) Examiner:
Application No. 10/820,479)
Filed: March 31, 2004)
For: USE OF ANGIOTENSIN RECEPTOR)
BLOCKERS (ARBS) TO TREAT)
DISEASES ASSOCIATED WITH)
EXCESS ACE)

PATENT
RECEIVED
CENTRAL FAX CENTER

MAR 08 2006

Via Facsimile to 571-273-8300

Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT


Attached is a copy of the Filing Receipt received from the PTO in the above-referenced patent application for which issuance of a corrected filing receipt is respectfully requested. The error is as follows:

The Domestic Priority data as claimed by applicant does not include 60/458,853 filed March 31, 2003 and 60/527,915 filed December 9, 2003.

The undersigned does not believe that a fee is due for this submission. However, the Commissioner is hereby authorized to charge any applicable fee to Deposit Account No. 19-3140.

Dated: March 8, 2006

Respectfully submitted,

By: 
Tara A. Nealey, Ph.D.
Registration No. 42,927
Customer No. 26263

22193289V-1

Early Publication Request: No

**** SMALL ENTITY ****

Title

Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier

license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).